Sept 1 (Reuters) - Sosei Group Corp
* Says co’s unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study
* Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016
Source text in Japanese: goo.gl/GiYgfQ
Further company coverage: (Beijing Headline News)
Our Standards: The Thomson Reuters Trust Principles.